The radioligand therapy (RLT) market growth continues to demonstrate resilience as the prostate cancer theranostics segment experiences explosive demand following regulatory approvals and compelling clinical trial data demonstrating overall survival benefits for lutetium-177 PSMA-617 in metastatic castration-resistant prostate cancer. Prostate-specific membrane antigen targeting represents the...